Top Page
Q-linea AB
(QLINEA)
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Q-linea AB Business Overview & Revenue Model
Q-linea AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.39M | 2.36M | 4.44M | 12.79M | 9.34M | 243.00K |
| Gross Profit | -49.07M | -11.11M | 995.00K | -21.38M | -25.03M | -32.02M |
| EBITDA | -167.24M | -195.40M | -210.99M | -252.69M | -218.48M | -211.02M |
| Net Income | -188.37M | -216.87M | -229.37M | -275.77M | -233.18M | -220.19M |
Balance Sheet | ||||||
| Total Assets | 155.38M | 147.99M | 231.98M | 207.39M | 466.63M | 412.23M |
| Cash, Cash Equivalents and Short-Term Investments | 42.58M | 25.66M | 81.89M | 72.62M | 166.03M | 306.89M |
| Total Debt | 47.86M | 151.21M | 20.56M | 20.93M | 79.00K | 331.00K |
| Total Liabilities | 67.93M | 175.45M | 42.34M | 45.76M | 35.84M | 32.03M |
| Stockholders Equity | 87.45M | -27.46M | 189.64M | 161.63M | 430.79M | 380.20M |
Cash Flow | ||||||
| Free Cash Flow | -171.35M | -187.49M | -236.86M | -268.11M | -267.02M | -250.53M |
| Operating Cash Flow | -163.79M | -182.50M | -228.52M | -250.86M | -255.05M | -237.31M |
| Investing Cash Flow | -6.56M | -5.04M | -7.77M | 315.25M | -23.82M | -32.30M |
| Financing Cash Flow | 205.60M | 131.27M | 245.41M | -6.60M | 283.81M | 253.78M |
Q-linea AB Technical Analysis
Q-linea AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | kr3.46B | -6.67 | -71.87% | ― | -91.85% | -6.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr201.83M | -2.51 | -51.35% | ― | ― | -34.02% | |
44 Neutral | kr121.23M | -0.77 | -72.82% | ― | 40.91% | 57.92% | |
44 Neutral | kr559.21M | -0.39 | -35.70% | ― | -18.46% | 4.90% | |
43 Neutral | kr487.77M | -0.28 | -330.10% | ― | 270.64% | 62.29% | |
42 Neutral | kr37.01M | -0.24 | -199.25% | ― | ― | 0.30% |
Q-linea AB Corporate Events
Q-linea has announced a reshaping of its US commercial leadership, with VP US Commercial Operations Jim Kathrein set to step down and support a transition during the first quarter of 2026, while Ethan Suttles, currently US Director of Strategic Accounts, will assume leadership of the US sales team and report directly to CEO Stuart Gander from 1 February 2026. The company is consolidating its US-based global leadership structure by having Natalie Brown, Director Global Marketing, and Vikas Gupta, Senior Director of Clinical Affairs, report directly to the CEO as well, underscoring a sharpened focus on executing Q-linea’s commercial strategy in the key US diagnostics market and accelerating the conversion of its growing ASTar® pipeline into routine clinical use heading into 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has signed its first distribution agreement in South Asia with Genetic Trading, a leading Bangladeshi distributor, in a move that advances the company’s global expansion strategy. Genetic Trading is completing product registration in Bangladesh, after which the first ASTar instrument order will be deployed for evaluation at a major hospital, positioning Q-linea to address the region’s significant sepsis and antimicrobial resistance challenges and laying the groundwork for broader South Asian market entry targeted for 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has been selected to supply its ASTar rapid antimicrobial susceptibility testing system to several Italian laboratories to meet tender obligations following the market withdrawal of the Accelerate Pheno rapid AST system. The company is working closely with affected labs to ensure a swift transition, with customers citing ASTar’s ease of use, broad organism and antibiotic coverage, and high-throughput capabilities, and Q-linea is also assessing additional demand from former Pheno users seeking a reliable replacement solution.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has achieved its first clinical implementations of the ASTar rapid antibiotic susceptibility testing system in the United States, with University of Iowa Health Care and a major Texas healthcare system now using the instrument. At UI Health Care, ASTar will expand statewide blood culture testing capacity, enabling faster selection of effective antibiotics for septic and other critically ill patients, and is expected to improve outcomes, reduce time to optimal therapy and streamline laboratory workflows through features such as full automation, high-throughput random-access testing, broad antibiotic panels and direct integration with Epic’s electronic medical record system, strengthening Q-linea’s foothold in the US hospital market for rapid AST solutions.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has increased its total number of shares and votes to 18,949,081 as of November 28, 2025, following a rights issue and a directed issue of shares. This expansion in share capital is a strategic move to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities in the healthcare sector.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has announced a reorganization and changes in its executive leadership team, aiming to enhance its commercial focus and operational efficiency. The restructuring includes a reduction of 16 employees in Sweden, with no impact on operations in the US and Italy, and the appointment of Ylva Molin to the Executive Management Group as Manager of Assay Development, while Jonas Melin transitions to a Senior Technical Advisor role and CFO Christer Samuelsson plans to depart.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has submitted a 510(k) application to the FDA for expanded organism and antimicrobial claims on their ASTar BC G- panel, enhancing its clinical utility for treating bacteremia and sepsis. This move follows a successful clinical trial and aims to align the FDA-cleared panel with its EU counterpart, potentially increasing its adoption in the US market, with a second FDA clearance expected by spring 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB, a company listed on Nasdaq Stockholm, has resolved to issue 16,800 shares as guarantee compensation to Wellsford Limited, deviating from shareholders’ preferential rights. This decision follows a successful capital raising effort and aims to complete the preferential rights issue, benefiting the company and its shareholders by increasing the share capital and ensuring financial stability.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB announced the outcome of its rights issue, which was subscribed to 97.1 percent, raising approximately SEK 312 million before transaction costs. This capital increase will significantly enhance Q-linea’s financial position, potentially impacting its market operations and stakeholder interests, especially considering the dilution effect of approximately 66 percent.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB, listed on Nasdaq Stockholm, has published a prospectus for its upcoming rights issue, which was approved by its board and an extraordinary general meeting. The rights issue aims to strengthen the company’s financial position, with Handelsbanken and Advokatfirman Lindahl serving as financial and legal advisors, respectively. The prospectus is available on Q-linea’s and the Swedish Financial Supervisory Authority’s websites.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea has announced a cost efficiency program aimed at reallocating resources from development to market-facing roles, particularly in the US, while reducing operational costs by 10% from Q3 2025 levels. This strategic move follows the completion of major development projects and aims to enhance profitability and achieve breakeven by 2027. The company will consolidate its Swedish offices and continue to focus on expanding its ASTar testing menu, which is expected to drive sales growth.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB held an extraordinary general meeting where shareholders approved a resolution to issue new shares with preferential rights for existing shareholders, increasing the company’s share capital significantly. This move is aimed at strengthening the company’s financial position and supporting its growth strategy. Additionally, amendments to the articles of association were made to accommodate the new share structure, and the board was authorized to issue shares to guarantors of the rights issue, reflecting strategic financial maneuvers to ensure the company’s robust market positioning.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB’s Q3 2025 report highlights significant growth in their ASTar platform, with new contracts in the US, Italy, and Saudi Arabia, and increased demand for consumables. The company’s strategic partnerships with pharmaceutical firms aim to expand the ASTar menu, while internalizing consumable production reduces costs. Despite a setback in the ESTAR tender appeal, Q-linea’s pipeline is robust, driven by the discontinuation of the Pheno platform by a competitor. A rights issue of SEK 322 million is set to support their goal of breakeven by 2027, as they continue to focus on customer-centric and cost-efficient operations.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has announced the appointment of Stuart Gander as the new CEO, with Anders Ljunggren transitioning to the role of deputy CEO. This leadership change is seen as a natural progression, given Gander’s prior role as president of the Q-linea group and his recent residency in Sweden, which aligns with the company’s strategic goals and operational continuity.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.